396 related articles for article (PubMed ID: 26202377)
1. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Yu X; Li Z; Yu J; Chan MT; Wu WK
Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
[TBL] [Abstract][Full Text] [Related]
2. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Kjersem JB; Ikdahl T; Lingjaerde OC; Guren T; Tveit KM; Kure EH
Mol Oncol; 2014 Feb; 8(1):59-67. PubMed ID: 24119443
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
4. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
6. Role of genomic markers in colorectal cancer treatment.
Allen WL; Johnston PG
J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
[TBL] [Abstract][Full Text] [Related]
7. Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
Lyskjær I; Rasmussen MH; Andersen CL
Epigenomics; 2016 Nov; 8(11):1449-1452. PubMed ID: 27779424
[No Abstract] [Full Text] [Related]
8. Which drug combination for colorectal cancer?
Doggrell SA
Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Jensen NF; Smith DH; Nygård SB; Rømer MU; Nielsen KV; Brünner N
Scand J Gastroenterol; 2012 Mar; 47(3):340-55. PubMed ID: 22181013
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
11. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.
Xie T; Huang M; Wang Y; Wang L; Chen C; Chu X
Cell Physiol Biochem; 2016; 40(1-2):62-76. PubMed ID: 27842308
[TBL] [Abstract][Full Text] [Related]
14. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
15. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Ho C; Ng K; O'Reilly S; Gill S
Clin Colorectal Cancer; 2005 Nov; 5(4):279-82. PubMed ID: 16356306
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy in patients with metastatic colorectal cancer.
Venook AP
Semin Oncol; 2003 Aug; 30(4 Suppl 12):25-9. PubMed ID: 14508724
[No Abstract] [Full Text] [Related]
18. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Kopetz S; Morris VK; Parikh N; Overman MJ; Jiang ZQ; Maru D; Elvin P; Gallick G
BMC Cancer; 2014 Sep; 14():660. PubMed ID: 25208577
[TBL] [Abstract][Full Text] [Related]
19. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
